Alhemo Injection, Solution
NDC 0169-2080
Product Information
Alhemo (concizumab) is a BLA-approved product labeled by Novo Nordisk. This medication is typically used as a tissue factor pathway inhibitor antagonist [epc]. It is supplied as a injection, solution for subcutaneous administration. This product entry covers the primary NDC 0169-2080 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0169-2080?
What are the uses of this product?
What are Active Ingredients of this product?
- CONCIZUMAB 100 mg/mL - blocked the interaction between FXa and factor pathway inhibitor in a rabbit hemophilia model
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CONCIZUMAB (UNII: 68603V9EAF)
- CONCIZUMAB (UNII: 68603V9EAF) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ARGININE (UNII: 94ZLA3W45F)
- HISTIDINE (UNII: 4QD397987E)
- PHENOL (UNII: 339NCG44TV)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SUCROSE (UNII: C151H8M554)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2708346 - concizumab-mtci 60 MG in 1.5 ML Pen Injector
- RxCUI: 2708346 - 1.5 ML concizumab-mtci 40 MG/ML Pen Injector
- RxCUI: 2708346 - concizumab-mtci 60 MG per 1.5 ML Pen Injector
- RxCUI: 2708353 - Alhemo 60 MG in 1.5 ML Pen Injector
- RxCUI: 2708353 - 1.5 ML concizumab-mtci 40 MG/ML Pen Injector [Alhemo]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.